ArticlePloS one2022
A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer.
Yash B Shah et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it